A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
← catalyst calendarNCT05094336 · readout in 102 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
329actual
Sites
75
Countries
Australia, Austria, Belgium +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-01 | actual | When the study began enrolling |
| Primary completion | 2026-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced MTAP-null Solid Tumors
Interventions
- Drug: Anvumetostat — also filed as MTA Cooperative PRMT5 inhibitor, AMG 193
- Drug: Docetaxel
- Drug: Comparator Anvumetostat Test Tablet
Primary outcomes
what the primary-completion date above is the date OFParts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
measured 28 days
Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
measured Up to approximately 3 years
Part 3: Objective Response Rate (ORR)
measured Up to approximately 3 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed